Mohammad Yousuf, MD
Internal Medicine · Dyersburg, TNNPI 1881634103
Payments from drug & device makers
Across 563 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- AbbVie$945
- Amgen$748
- Mylan Specialty L.p.$743
- Sunovion Pharmaceuticals Inc.$613
- plus $5K from 39 others
What the payments were for
- Consulting fees$1,54513%
- Speaking & faculty fees$3703%
- Food & beverage$10,30984%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$714
- BREZTRI$443
- SYMBICORT$375
- UBRELVY$250
- AIRSUPRA$219
- BREZTRI AEROSPHERE$142
- BEVESPI AEROSPHERE$128
How this compares
$12,233 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 222 | $147,251 |
| RexultiBrexpiprazole | 72 | $99,074 |
| VraylarCariprazine Hcl | 87 | $91,859 |
| CreonLipase/Protease/Amylase | 53 | $83,642 |
| OzempicSemaglutide | 88 | $82,749 |
| JardianceEmpagliflozin | 124 | $76,444 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 121 | $75,077 |
| RybelsusSemaglutide | 57 | $74,002 |
| FarxigaDapagliflozin Propanediol | 72 | $61,475 |
| MounjaroTirzepatide | 57 | $60,573 |
| LinzessLinaclotide | 90 | $59,329 |
| EntrestoSacubitril/Valsartan | 52 | $43,136 |
| JanumetSitagliptin Phos/Metformin Hcl | 56 | $42,043 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $35,801 |
| EliquisApixaban | 115 | $21,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Creon, Linzess, Ubrelvy | $945 | $250,979241 claims |
| Novo NordiskOzempic, Rybelsus | $544 | $156,751145 claims |
| GSKTrelegy Ellipta | $2,291 | $147,251222 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $1,515 | $136,552193 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Trijardy Xr | $234 | $118,546209 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $388 | $99,07472 claims |
| MerckJanumet, Januvia | $474 | $61,720125 claims |
| Lilly USA, LLCMounjaro | $360 | $60,57357 claims |
| NovartisEntresto | $64 | $43,13652 claims |
| PfizerEliquis, Premarin | $163 | $24,370131 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $93 | $17,87984 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $22 | $15,91213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Dyersburg
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.